Antibody Therapeutics Xchange Europe

Target Selection

Titles and Bullets
8:30am – 9:00am

Opening Address & Keynote: What Makes Data Physiologically Relevant? Thomas Glass, Senior Scientist, Sapidyne Instruments

9:05am – 10:05am

Finding the best targets and binder combination for bi- or multispecific antibodies

  • The use of standard therapeutic antibodies created with conventional lead generation processes have reached their limitations. New target combinations, exploiting rare epitopes or identifying novel bispecific combinations in different antibody formats are urgently needed to find novel applications in various disease settings. 
  • How do we best select new target (and epitope) combinations that are biologically meaningful and hold promise to tackle novel disease biology?
  • How can we generate maximal binder and antibody format diversity to identify highly differentiated biologics?
  • What are our experiences and learnings from the use of novel high-throughput technologies and combinatorial platforms to rapidly generate bispecific antibody combinations in differing formats that offer tailored solutions and novel mode-of-actions to address challenging biology

Christian Kunz


Portrait picture of Christian Kunz
10:10am – 10:40am

1-2-1 Meetings

10:45am – 11:45am

Off limits or fair game? Antibody drug discovery for complex targets
  • Is this class of targets feasibly addressable or purely aspirational?
  • What are the notable advances/inroads?
  • Are there particular challenges and limitations to the ‘TCR mimic’ antibody approach?

Head, Antibody Research

Stephen Hearty joined Immunocore in 2014 to establish the Autoimmune Research arm and subsequently he also established the Antibody Research group which he currently heads with a broad research remit spanning both discovery research and platform development efforts. He obtained his Ph.D. in Applied Biochemistry from Dublin City University in 2005 specialising in novel antibody generation and has continued to work extensively across the antibody field.

Portrait picture of Stephen Hearty
11:50am – 12:20pm
1-2-1 Meetings
12:20pm – 1:00pm

Lunch Break

1:35pm – 2:35pm

How to select targets for immunotherapy combinations

  • Immunotherapy targeting PD-1/PD-L1 or CTLA-4 has shown impressive results in various cancer indications; however, only a subset of patients respond to single agent therapy.
  • Combination immunotherapy presents an opportunity for improving responses and outcomes for cancer patients.
  • Currently, 1000s of combination trials are ongoing.
  • The development of immunotherapy combinations faces a number of challenges, including selection and validation of targets

Project & Portfolio Director

Johan Lantto is a Project & Portfolio Director at Symphogen, a Danish antibody-focused biotech company. Johan holds a Ph.D. in Immunotechnology from Lund University, Sweden, where he studied antibody evolution and repertoire development. Johan has more than 20 years of experience with antibody engineering and the development of antibodies. For the past 16 years, he has been involved in the development of antibody technology platforms as well as heading antibody drug discovery/development projects within infectious disease and oncology. Johan is currently heading Symphogen’s Immuno-oncology program aimed at developing novel therapeutic antibodies and antibody combinations for cancer immunotherapy.

Portrait picture of Johan Lantto

11:50am – 12:20pm

1-2-1 Meetings

11:50am – 12:20pm

1-2-1 Meetings

4:50pm – 4:55pm

Closing Address


Antibody Therapeutics Xchange | Europe